Working with the life sciences industries to create value / Sir Andrew Dillon,  chief executive of the National Institute for Clinical Excellence (NICE)
Upcoming SlideShare
Loading in...5
×
 

Working with the life sciences industries to create value / Sir Andrew Dillon, chief executive of the National Institute for Clinical Excellence (NICE)

on

  • 742 views

Sir Andrew Dillon, director general del National Institute for Health & Clinical Excellence (NICE) del Regne Unit, va ser l’encarregat d’oferir la conferència central del Fòrum, en la qual va ...

Sir Andrew Dillon, director general del National Institute for Health & Clinical Excellence (NICE) del Regne Unit, va ser l’encarregat d’oferir la conferència central del Fòrum, en la qual va explicar l’experiència de l’entitat que dirigeix —una referència internacional en el seu àmbit— en valorització de la recerca i, sobretot, l’apropament de les necessitats del sistema públic de salut (les necessitats dels pacients i els requeriments tècnics dels professionals) a la indústria farmacèutica i de les tecnologies mèdiques.

Statistics

Views

Total Views
742
Views on SlideShare
741
Embed Views
1

Actions

Likes
0
Downloads
4
Comments
0

1 Embed 1

http://www.linkedin.com 1

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

CC Attribution-NonCommercial-NoDerivs LicenseCC Attribution-NonCommercial-NoDerivs LicenseCC Attribution-NonCommercial-NoDerivs License

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Working with the life sciences industries to create value / Sir Andrew Dillon,  chief executive of the National Institute for Clinical Excellence (NICE) Working with the life sciences industries to create value / Sir Andrew Dillon, chief executive of the National Institute for Clinical Excellence (NICE) Presentation Transcript

  • Working with the life sciencesindustries to create valueBiocatBarcelona, 24 NB l November 2011 b
  • The purpose of NICE• H l th h lth service i Help the health i improve th quality of care the lit f• Increase the rate of adoption of effective and cost effective new technologies by the health system• Work with companies to help them understand what the health system needs and how the additional value that thier products bring to patients is assessed
  • Health technologies• Pharmaceuticals Ph ti l• Biotech• Diagnostics Di ti• Medical devices• We want to see products which bring additional diagnostic and th di ti d therapeutic b ti benefit f patients and fit for ti t d which make good use of health system resources
  • NICE: defining value Outcomes for patients Impact onStakeholder healthperspectives system resources Scientific and social value judgements
  • NICE: NICE cost effectiveness analysis t ff ti l i 1 xProbability ofrejection j Rituximab for x Imatinib for follicular lymphoma chronic myeloid leukaemia (blast phase) Trastuzumab for early stage HER-2 positive b iti breast t x cancer 0 16 32 48 64 80 Cost per QALY ($’000)
  • Most new health technologies bring additional valueDecisionD i i Recommendations R d iYes 276 (63%) 82% of NICE advice is positiveOptimised 83 (19%)Only in research 24 (5%)No 55 (13%)Breakdown of all decisions contained in published NICE Technology Appraisals p gy pp1–236 (January 2000 to October 2011)Note: 6 withdrawn recommendations and 10 non-submissions are not included
  • Helping innovators understand value• Early t E l stage scientific advice i tifi d i• Wider definition of value• Transparent and inclusive evaluative processes T t di l i l ti• Clear and detailed guidance• Targeted research questions
  • Helping innovators understand value• Early t E l stage scientific advice i tifi d i• Wider definition of value• Transparent and inclusive evaluative processes T t di l i l ti• Clear and detailed guidance• Targeted research questions
  • Scientific Advice Programme• I t Interpretation of NICE t h l t ti f technology appraisal methods i l th d guidance• Research design (study population duration population, duration, comparators, endpoint(s), type of study)• Economic evaluation design (e g form of evaluation (e.g. and approaches to benefit measurement; relevant trial(s) for economic evaluation; the use of (QALYs) ( ) ( )• Methods issues (e.g. selection of instruments / research to derive QALYs; extrapolation of long-term outcomes; planning for indirect comparisons)• Insights from existing appraisals
  • Value based pricing• R Recent UK G t Government proposals (to be i t d t l (t b introduced d from 2014) designed to extend the definition of value in UIK drug appraisal and reimbursement decisions decisions.• Increased focus on: – Wider societal benefits – Products which address areas of unmet need or high burden of illness – New products with particularly innovative features• Seen as an evolution of and not a replacement for the PPRS and NICE arrangements
  • Conclusion• I Innovators and health systems need t work t t d h lth t d to k together to th t create and deliver value for patients• We need to establish the earliest possible dialogue between companies and agencies that assess new technologies• Health systems – and the agencies that work for them have a responsibility to support innovation and to work p y pp constructively with the companies that deliver it